NCNA NuCana: Earnings per share for the last 12 months

NuCana Corp (NCNA) - corporate logo

NuCana plc develops nucleoside agents to combat tumor chemoresistance within the B2B segment. This innovative method enables the destruction of cancer cells from within, enhancing therapy safety. This YoY TTM earnings per share chart reflects performance dynamics, where the most recent value is recorded as 98.50. The absence of commercial products makes the biotech's valuation exclusively dependent on the outcomes of current clinical trials.

NuCana Corp (NCNA) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026
Flagship merchandise of NuCana PLC

NuCana plc (NCNA) is developing the innovative ProTide ecosystem, transforming chemotherapy delivery in oncology. By analyzing the YoY ttm earnings per share dynamics, an investor assesses the real rate of change in net income over the last twelve months. This filter eliminates subjectivity, revealing the gap between market price and fundamental value. Regular monitoring of the curve prevents the purchase of overvalued assets at their peak, which is critical for capital risk control.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Silexion (SLXN)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months